Assertio Holdings, Inc. (NASDAQ: ASRT) related to its sale to Garda Therapeutics, Inc. Under the terms of the proposed transaction, Assertio shareholders are expected to receive $18.00 in cash per share plus one contingent value right per share based on certain milestones.